Toronto, ON (PRWEB) June 29, 2016
ProMIS Neurosciences (“ProMIS” or the “Company”), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that two presentations will be made on its recent therapeutic developments at the Alzheimer’s Association International Conference being held from July 24th to 28th, 2016 in Toronto, Ontario, Canada.
"These presentations detail the scientific work conducted to identify the five novel targets and multiple associated therapeutic candidates for Alzheimer’s disease (“AD”) that ProMIS recently announced," said Dr. Neil Cashman, ProMIS’ Chief Science Officer. "This work enabled ProMIS to progress multiple successfully screened monoclonal antibodies (“mAbs”) to the ongoing validation stage. We are now evaluating binding profiles in cadaveric brain tissue from AD patients to identify the product candidates to progress to drug development.”
The first presentation, entitled A Computational Method to Predict Disease-Specific Epitopes in Aβ, and Its Application to Oligomer-Selective Antibodies for Alzheimer’s Immunotherapy, is a poster authored by Dr. Steven Plotkin (et al.), the Company’s Chief Physics Officer. The authors describe one of the Company’s unique, proprietary discovery platforms, Collective Coordinates, to predict novel therapeutic targets on prion-like strains of Amyloid beta (Aβ), implicated in the development and progression of AD. The data demonstrate that the novel targets identified by Collective Coordinates can be used to raise multiple mAbs that specifically target the neurotoxic, prion-like strains of Aβ.
The second presentation entitled Novel Amyloid-β Oligomer-Specific Epitopes: A Hypothesis Driven Approach to Alzheimer's Immunotherapeutics, is a poster authored by University of British Columbia’s Dr. Judith Silverman (et al.), whose work was conducted in the lab of Dr. Neil Cashman, the Company’s Chief Science Officer and Co-founder. The authors describe the screening process for initial identification of mAb therapeutic candidates that specifically and selectively bind to the previously mentioned five novel AD targets with little or no measurable off-target binding. The authors then describe the process for validation of the successfully screened product candidates, particularly, the evaluation of binding profiles in cadaveric brain tissue from AD patients, to identify the lead products to progress to drug development.
About ProMIS Neurosciences, Inc.
The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.
ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platforms—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has three preclinical monoclonal antibody therapeutics against this target.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. The information in this release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information please consult the Company's website at:
Follow us on Twitter
Like us on LinkedIn
Michael Moore: mmoore(at)national(dot)ca
Abby Garfunkel: agarfunkel(at)national(dot)ca
Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783